On 2 February 2026, Alvotech announced that it has entered into supply and commercialisation agreements with Sandoz for multiple unidentified biosimilars for Australia, New Zealand and Canada.
In Australia and New Zealand, the agreement covers three biosimilars across immunology and gastroenterology, whilst the agreement in Canada covers an ophthalmology biosimilar supplied as a prefilled syringe for intravitreal injection.
Under the agreements, Sandoz will lead the regulatory submissions, commercialisation and distribution in the relevant jurisdictions, and Alvotech retains responsibility for development, manufacture and supply of the products to Sandoz.
Alvotech has a number of ophthalmology and immunology/gastroenterology biosimilars in its pipeline. In relation to ophthalmology, Alvotech has received approval for AVT06 (Mynzepli® (aflibercept), 2mg) in the EU, UK and Japan (Sandoz has its own aflibercept 2mg biosimilar (Afqlir®/Enzeevu®) which has been approved in a number of jurisdictions). Alvotech is also developing AVT29, a biosimilar to Regeneron/Bayer’s Eylea™ 8mg. In June 2024, Alvotech entered into an agreement with Advanz Pharma in relation to the commercialisation of AVT29 in Europe. Teva holds commercialisation rights for AVT29 (and AVT06, aflibercept 2mg) in the US. In the immunology and gastroenterology fields, Alvotech has received approval for AVT05 (golimumab) in Japan, the UK and the EU and is developing AVT16 (vedolizumab), AVT10 (certolizumab pegol), AVT28 (ixekizumab), AVT48 (canakinumab), AVT41 (guselkumab), AVT65 (ofatumumab), and AVT19 (dupilumab).